Phase 2 Study of Tripegfilgrastim to Lower Severe Neutropenia Risk
in Adults With Unresectable Pancreaticobiliary Cancer Receiving Nal-IRI5-FULV Chemotherapy
A Randomized, Open-Label Multicenter Trial
Led by National Cancer Center, Korea · Updated on 2025-06-18
98
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the effects of tripegfilgrastim on preventing severe neutropenia in patients with unresectable pancreaticobiliary cancers receiving nal-IRI5-FULV combination chemotherapy. Pancreatic and bile duct cancers have poor survival rates, especially when unresectable, and this study explores the potential benefit of using a pegylated granulocyte colony-stimulating factor G-CSF to reduce complications like neutropenia, which can occur during chemotherapy. The study is a phase 2, randomized controlled trial conducted at multiple centers.
Participants will be randomly assigned to receive either the experimental treatment including tripegfilgrastim or a control regimen without it. Both groups receive chemotherapy every two weeks with premedications and infusions of Onivyde, leucovorin, and 5-FU. In the experimental group, tripegfilgrastim 6 mg is given subcutaneously 24 hours after completing 5-FU infusion to help reduce neutropenia risk. The control group receives the same chemotherapy but tripegfilgrastim is only given if febrile neutropenia occurs, with treatment paused until recovery.
Participants will be followed through the intervention period until disease progression or unacceptable toxicity, with survival assessed every two months. Researchers will monitor neutropenia incidence, febrile neutropenia, emergency visits, overall survival, progression-free survival, and biomarkers for about one year. The total study duration extends until June 2026, including follow-up and statistical analysis periods. Safety and treatment effects will be carefully evaluated throughout the study.
CONDITIONS
Brief Title
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Research Team
S
Sangmyung Woo, M.D
J
Jung Won Chun, M.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with unresectable pancreaticobiliary cancer
Scheduled to receive nal-IRI/5-FU/LV combination chemotherapy
You will not qualify if you...
Patients who refuse to sign the consent form
Patients who have previously experienced severe neutropenia during chemotherapy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 1 year
Participants receive nal-IRI/5-FU/LV combination chemotherapy every two weeks. Those in the treatment group also receive Tripegfilgrastim 24 hours after completing 5-FU infusion to reduce the risk of severe neutropenia. Participants in the control group may receive Tripegfilgrastim if febrile neutropenia develops, and chemotherapy may be paused until recovery.
Visits every 2 weeks during chemotherapy
Follow-up
Duration - Up to 1 year
Participants are monitored for outcomes including neutropenia incidence, febrile neutropenia, emergency department visits, overall survival, progression-free survival, and biomarkers through study completion.
Periodic visits depending on clinical needs
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Evaluating Safety and Early Effectiveness of Autologous Drug-Loaded Neutrophils NeuMed with Monomethyl Auristatin E in Adults Aged 18-70 with Unresectable Pancreatic Cancer
Study of Adebrelimab Combined with Apatinib and Gemcitabine-Cisplatin as First Treatment for Unresectable Advanced Biliary Tract Cancer
Study on Safety and Feasibility of Intratumoral Alpha Radiation Device for Advanced Pancreatic Cancer Treatment
Feasibility and Safety Study of Intratumoral Alpha Radiation Device for Advanced Pancreatic Cancer Treatment
Evaluating Alternating Cycles of Chemoimmunotherapy and Pemigatinib for Advanced FGFR2-Positive Biliary Tract Cancer
Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy with Standard Care for Patients with Unresectable Pancreatic Cancer
Study of AGuIX Nanoparticles With MR-Guided Stereotactic Body Radiation Therapy for Lung Tumors and Advanced Pancreatic Cancer
Phase I-II Trial to Evaluate Safety and Effectiveness
Phase I Study to Assess Safety and Effectiveness of NRT6008 Injection Combined with Chemotherapy for Unresectable Locally Advanced and Advanced Pancreatic Cancer with Lymph Node Metastases
Study Comparing Trastuzumab Plus Chemotherapy Versus Chemotherapy Alone
for First Treatment of HER2-Positive Advanced or Metastatic Biliary Tract Cancer
A Randomized Phase III Clinical Trial
Phase 2 Study of Tripegfilgrastim to Lower Severe Neutropenia Risk
in Adults With Unresectable Pancreaticobiliary Cancer Receiving Nal-IRI5-FULV Chemotherapy
A Randomized, Open-Label Multicenter Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky...
Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment.
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.